These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 28286965)

  • 1. Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer.
    Murray HC; Dun MD; Verrills NM
    Expert Opin Drug Discov; 2017 May; 12(5):431-447. PubMed ID: 28286965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass spectrometry-based proteomics: from cancer biology to protein biomarkers, drug targets, and clinical applications.
    Jimenez CR; Verheul HM
    Am Soc Clin Oncol Educ Book; 2014; ():e504-10. PubMed ID: 24857147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of targeted mass spectrometry in bottom-up proteomics for systems biology research.
    Manes NP; Nita-Lazar A
    J Proteomics; 2018 Oct; 189():75-90. PubMed ID: 29452276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Big data' approaches for novel anti-cancer drug discovery.
    Benstead-Hume G; Wooller SK; Pearl FMG
    Expert Opin Drug Discov; 2017 Jun; 12(6):599-609. PubMed ID: 28462602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frontiers in mass spectrometry-based clinical proteomics for cancer diagnosis and treatment.
    Haga Y; Minegishi Y; Ueda K
    Cancer Sci; 2023 May; 114(5):1783-1791. PubMed ID: 36661476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis.
    Cha S; Lee J; Shin JY; Kim JY; Sim SH; Keam B; Kim TM; Kim DW; Heo DS; Lee SH; Kim JI
    BMC Cancer; 2016 Feb; 16():170. PubMed ID: 26925973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomics approaches for myeloid leukemia drug discovery.
    Kapoor I; Pal P; Lochab S; Kanaujiya JK; Trivedi AK
    Expert Opin Drug Discov; 2012 Dec; 7(12):1165-75. PubMed ID: 22971110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The contribution of mass spectrometry-based proteomics to understanding epigenetics.
    Noberini R; Sigismondo G; Bonaldi T
    Epigenomics; 2016 Mar; 8(3):429-45. PubMed ID: 26606673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification.
    Fu S; Liu X; Luo M; Xie K; Nice EC; Zhang H; Huang C
    Expert Rev Proteomics; 2017 Apr; 14(4):351-362. PubMed ID: 28276747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global MS-Based Proteomics Drug Profiling.
    Carvalho AS; Matthiesen R
    Methods Mol Biol; 2016; 1449():469-79. PubMed ID: 27613057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.
    Matta A; Ralhan R; DeSouza LV; Siu KW
    Mass Spectrom Rev; 2010; 29(6):945-61. PubMed ID: 20945361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of clinical proteogenomics in lung cancer.
    Nishimura T; Nakamura H; Végvári Á; Marko-Varga G; Furuya N; Saji H
    Expert Rev Proteomics; 2019 Sep; 16(9):761-772. PubMed ID: 31402712
    [No Abstract]   [Full Text] [Related]  

  • 13. Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach.
    Ali M; Khan SA; Wennerberg K; Aittokallio T
    Bioinformatics; 2018 Apr; 34(8):1353-1362. PubMed ID: 29186355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular insights into cancer drug resistance from a proteomics perspective.
    An Y; Zhou L; Huang Z; Nice EC; Zhang H; Huang C
    Expert Rev Proteomics; 2019 May; 16(5):413-429. PubMed ID: 30925852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy.
    Calvo KR; Liotta LA; Petricoin EF
    Biosci Rep; 2005; 25(1-2):107-25. PubMed ID: 16222423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing disease-associated changes in post-translational modifications by mass spectrometry.
    Thygesen C; Boll I; Finsen B; Modzel M; Larsen MR
    Expert Rev Proteomics; 2018 Mar; 15(3):245-258. PubMed ID: 29376447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer biomarker discovery and translation: proteomics and beyond.
    Hristova VA; Chan DW
    Expert Rev Proteomics; 2019 Feb; 16(2):93-103. PubMed ID: 30556752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mass spectrometry for proteomics-based investigation.
    Woods AG; Sokolowska I; Ngounou Wetie AG; Wormwood K; Aslebagh R; Patel S; Darie CC
    Adv Exp Med Biol; 2014; 806():1-32. PubMed ID: 24952176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detecting protein variants by mass spectrometry: a comprehensive study in cancer cell-lines.
    Alfaro JA; Ignatchenko A; Ignatchenko V; Sinha A; Boutros PC; Kislinger T
    Genome Med; 2017 Jul; 9(1):62. PubMed ID: 28716134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic Approaches for Biomarker Panels in Cancer.
    Tanase C; Albulescu R; Neagu M
    J Immunoassay Immunochem; 2016; 37(1):1-15. PubMed ID: 26565430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.